Largest-ever cannabis review finds no evidence it treats anxiety, depression, or PTSD

The largest systematic review of medicinal cannabis ever conducted has concluded that there is no reliable scientific evidence supporting its use for anxiety, depression, or PTSD. Millions of patients in countries where medicinal cannabis is legally available use it for exactly those conditions. The gap between what patients believe and what the evidence actually shows has now been quantified at scale, and the findings are uncomfortable for an industry that has grown rapidly on the back of those therapeutic claims.

The review was led by researchers at the University of Sydney's Matilda Centre and published in The Lancet Psychiatry. It analyzed data from 269 studies involving over 36,000 participants across a range of psychiatric and neurological conditions. For anxiety, depression, and PTSD specifically, the reviewers found that the available trial evidence was either too weak in study design, too small in sample size, or too inconsistent in outcome to support clinical conclusions. The word the researchers used repeatedly was 'insufficient.' That is a precise scientific term. It does not mean cannabis does not work for these conditions. It means the evidence required to say it does work does not yet exist.

What the review found and what it did not find

The review distinguished carefully between different conditions and different cannabis formulations. For chemotherapy-induced nausea and vomiting, the evidence was stronger, with cannabinoids showing consistent benefit across multiple well-designed trials. For chronic pain, the picture was mixed but more supportive than for mental health conditions. The mental health findings were the most stark, particularly because anxiety and depression are the most commonly cited reasons for medicinal cannabis use in countries like Australia, Canada, and the United Kingdom.

The review also found evidence of harm. Cannabis use was associated with increased rates of psychosis and psychotic symptoms, particularly in higher-potency THC products and in people with a personal or family history of psychotic disorders. Discontinuation symptoms, dependence, and worsening of depressive episodes in some patient populations were also documented. These are not theoretical risks. They appeared in the clinical trial data that the review analyzed.

Why there is so little high-quality trial data

Conducting rigorous randomized controlled trials on cannabis has been hampered by regulatory constraints and methodological challenges for decades. In the United States, cannabis remains a Schedule I controlled substance at the federal level, which creates significant barriers to research funding, participant recruitment, and product standardization for clinical trials. Most of the existing studies in the review were small, ran for short durations, used inconsistent dosing protocols, and defined outcomes in ways that made cross-study comparisons difficult.

The problem with CBD-specific research is worth noting separately. CBD products have been marketed aggressively for anxiety relief, with the global CBD market valued at approximately $9.3 billion in 2023 according to Grand View Research. Yet the clinical trial evidence base for CBD in anxiety disorders consists primarily of small proof-of-concept studies, a handful of trials in social anxiety disorder, and a limited number of longer-duration trials. The Lancet Psychiatry review included CBD studies and found the same pattern as for whole-plant cannabis products: preliminary signals but no confirmed efficacy from adequately powered trials.

The gap between patient experience and clinical evidence

Patient-reported improvements in anxiety and sleep from cannabis are common and well-documented in survey data. A 2020 study in the Journal of Affective Disorders analyzed data from the Strainprint app, which tracks self-reported symptom changes after cannabis use, and found that users reported short-term reductions in anxiety, depression, and stress after consumption. Those subjective reports are real. They reflect what people actually experience. But subjective improvement in the short term does not confirm clinical efficacy, particularly when placebo effects in psychiatric conditions are large and when longer-term outcome data is missing.

The review authors acknowledged this tension directly, noting that patient experience should not be dismissed but also cannot substitute for controlled trial evidence when establishing clinical recommendations. The researchers pointed out that cannabis users who report relief from anxiety may be experiencing reduced withdrawal symptoms from cannabis itself, acute intoxication effects, or genuine placebo response, rather than therapeutic action on the underlying anxiety disorder. Separating those effects requires blinded placebo-controlled trials, which are precisely what the evidence base is currently lacking.

Policy implications and prescribing guidelines

The review is expected to influence prescribing guidelines in Australia, where medicinal cannabis approvals through the Therapeutic Goods Administration have grown sharply since 2016, reaching over 350,000 approvals in 2023. Anxiety disorders account for the largest single category of approved indications. The Australian government's independent advisory committee on medicines has been reviewing the evidence base for medicinal cannabis since 2022, and the Lancet Psychiatry findings are likely to be incorporated into that ongoing review.

In the United Kingdom, the National Institute for Health and Care Excellence issued guidance in 2019 recommending against the use of cannabis-based medicinal products for anxiety, and the new review provides additional support for that position. Canada's prescribing framework allows physicians discretion in recommending cannabis for conditions where evidence is limited, but Health Canada's guidance documents note the absence of strong clinical trial data for psychiatric indications. The review authors called for international coordination on funding adequately powered trials in the next five years to resolve the evidence gaps rather than continuing to operate on the basis of insufficient data.